title: Novel therapies for chronic lymphocytic leukemia in the 21st century.
abstract: Chronic lymphocytic leukemia (CLL) is one of the most common types of leukemia diagnosed in the Western Hemisphere. Introduction of the purine analogs has improved outcome for patients with CLL as measured by improvements in disease-free survival and has made it possible to attain a complete remission in a minority of patients with this disease. The therapeutic success with the purine analogs in CLL has led to preclinical and early clinical investigation of a variety of other therapeutic agents. This, combined with advances in the understanding the genetic and immunobiology of CLL, leaves hope that CLL may become a curable disease in this century.
authors.affiliation: Division of Hematology-Oncology, Walter Reed Army Medical Center, Washington, DC 20307, USA.
authors.forename: J C
authors.initials: JC
authors.lastname: Byrd
authors.forename: J K
authors.initials: JK
authors.lastname: Waselenko
authors.forename: M
authors.initials: M
authors.lastname: Keating
authors.forename: K
authors.initials: K
authors.lastname: Rai
authors.forename: M R
authors.initials: MR
authors.lastname: Grever
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D018796:Immunoconjugates; D019275:Radiopharmaceuticals